Outlook Therapeutics to Participate in Cantor Fitzgerald’s Virtual Panel Discussion: Eyeing Key Events and Programs in the Ophthalmology Space in 2021

Rhea-AI Summary

Outlook Therapeutics (Nasdaq: OTLK) announced that its CEO, Lawrence A. Kenyon, will participate in a virtual panel on February 19, 2021, hosted by Cantor Fitzgerald. The panel, titled “Eyeing Key Events and Programs in the Ophthalmology Space in 2021,” aims to discuss market opportunities and upcoming milestones in the ophthalmology sector. Outlook Therapeutics focuses on developing ONS-5010 (bevacizumab-vikg), potentially the first FDA-approved ophthalmic formulation for retinal diseases like wet AMD.

MONMOUTH JUNCTION, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will participate in the Cantor Fitzgerald “Eyeing Key Events and Programs in the Ophthalmology Space in 2021” virtual panel being held on Friday, February 19, 2021 from 10:30 AM – 12:00 PM ET.

The panel, hosted by Kristen Kluska, Equity Research Analyst at Cantor Fitzgerald, will discuss market opportunities across numerous indications in the ophthalmology space and will include highlights from participating company pipelines, previously reported datasets, and upcoming 2021 milestones and events.

To attend the virtual panel, please register in advance here.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:

Media Inquiries:
Harriet Ullman
Assistant Vice President
LaVoieHealthScience
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247 
OTLK@jtcir.com

FAQ

What is the upcoming virtual panel featuring Outlook Therapeutics?

The virtual panel hosted by Cantor Fitzgerald, titled 'Eyeing Key Events and Programs in the Ophthalmology Space in 2021,' will take place on February 19, 2021.

Who is participating in the Cantor Fitzgerald virtual panel?

Lawrence A. Kenyon, CEO of Outlook Therapeutics, will participate in the panel.

What is Outlook Therapeutics developing?

Outlook Therapeutics is developing ONS-5010 (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation for treating retinal diseases.

What conditions does ONS-5010 aim to treat?

ONS-5010 aims to treat conditions such as wet AMD, diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).

When does Outlook Therapeutics plan to file with the FDA?

Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway for wet AMD.